EASE LID 2 Study

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Topic / Pathology

  • Parkinson's Disease

Objectives

To have more informations, click on the link below: 

https://clinicaltrials.gov/ct2/show/NCT02202551?term=Adamas&cond=parkinson&cntry=FR&draw=2&rank=4

Sponsor

Adamas Pharmaceuticals, Inc.

Scientific publication(s)

  • Hauser RA et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis. 2017;7(3):511-522

    https://pubmed.ncbi.nlm.nih.gov/28777755/

Status

Published results

Participating centers

Share

Updated on 17 February 2023